TEST:

PreciseDx Breast Test

"PreciseDx®...announced a sponsored research collaboration with UCLA's Department of Pathology and Laboratory Medicine in Los Angeles to evaluate PreciseBreast's™ ability to accurately assess risk of recurrence for patients with triple-negative breast cancer (TNBC). TNBC constitutes only 10-20% of all breast cancer cases, yet continues to demand significant clinical interest due to its limited response to conventional treatments, the association with younger women, BRCA1/2 mutations, ethnic/racial disparities, and its highly aggressive characteristics."

"PreciseDx®...announced their attendance and participation at the 14th Annual European Breast Conference in Milan, Italy...is presenting the findings from the PreciseBreast™ biopsy clinical validation study through a poster presentation."

"PreciseDx...collaborating with Baylor Scott & White Health in Texas to validate its PreciseBreast assessment for early-stage invasive breast cancer."

In summary, the analytical validation of the digital IBC risk assessment test demonstrated a strong performance across all features in the model and complimented the clinical validation of the assay previously shown to accurately predict recurrence within 6-years in early-stage invasive breast cancer patients.

"PreciseDx...announced that its analytical validation study for its PreciseBreast assessment has been published in the November 3, 2023 issue of Clinical Breast Cancer."

"PreciseDx...announced that the New York State Department of Health (NYSDOH) has approved the PDxBr, a Lab Developed Test (LDT) designed to enrich breast cancer grading and improve risk categorization. With this approval, PreciseDx can now begin commercially testing patient samples in the state of New York through its CLIA certified laboratory."

"PreciseDx...announced a sponsored research collaboration with the Breast Unit of the Champalimaud Clinical Center (CCC)/Champalimaud Foundation in Lisbon, Portugal...As part of the research collaboration, PreciseDx and the CCC will evaluate the performance of the PreciseDx Breast Assay in predicting breast cancer recurrence and treatment choice."